Patterns and rates of exonic de novo mutations in autism spectrum disorders by Neale, Benjamin Michael et al.
 
Patterns and rates of exonic de novo mutations in autism spectrum
disorders
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Neale, Benjamin M., Yan Kou, Li Liu, Avi Ma'ayan, Kaitlin E.
Samocha, Aniko Sabo, Chiao-Feng Lin, et al. 2013. Patterns and
rates of exonic de novo mutations in autism spectrum disorders.
Nature 485(7397): 242-245.
Published Version doi:10.1038/nature11011
Accessed February 19, 2015 12:06:28 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11365694
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAPatterns and rates of exonic de novo mutations in autism
spectrum disorders
Benjamin M. Neale1,2, Yan Kou3,4, Li Liu5, Avi Ma'ayan3, Kaitlin E. Samocha1,2, Aniko
Sabo6, Chiao-Feng Lin7, Christine Stevens2, Li-San Wang7, Vladimir Makarov4,8, Paz
Polak2,9, Seungtai Yoon4,8, Jared Maguire2, Emily L. Crawford10, Nicholas G. Campbell10,
Evan T. Geller7, Otto Valladares7, Chad Shafer5, Han Liu11, Tuo Zhao11, Guiqing Cai4,8,
Jayon Lihm4,8, Ruth Dannenfelser3, Omar Jabado12, Zuleyma Peralta12, Uma Nagaswamy6,
Donna Muzny6, Jeffrey G. Reid6, Irene Newsham6, Yuanqing Wu6, Lora Lewis6, Yi Han6,
Benjamin F. Voight2,13, Elaine Lim1,2, Elizabeth Rossin1,2, Andrew Kirby1,2, Jason
Flannick2, Menachem Fromer1,2, Khalid Shakir2, Tim Fennell2, Kiran Garimella2, Eric
Banks2, Ryan Poplin2, Stacey Gabriel2, Mark DePristo2, Jack R. Wimbish14, Braden E.
Boone14, Shawn E. Levy14, Catalina Betancur15, Shamil Sunyaev2,9, Eric Boerwinkle6,16,
Joseph D. Buxbaum4,8,12,17,°, Edwin H. Cook Jr.18, Bernie Devlin19, Richard A. Gibbs6,
Kathryn Roeder5,°, Gerard D. Schellenberg7, James S. Sutcliffe10, and Mark J. Daly1,2,°
1Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General
Hospital and Harvard Medical School, Boston, Massachusetts, 02114
2Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, 7 Cambridge
Center, Cambridge, Massachusetts, 02142
3Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, New
York, 10029
4Seaver Autism Center for Research and Treatment, Mount Sinai School of Medicine, New York,
New York, 10029
5Department of Statistics, Carnegie Mellon University, Pittsburgh, Pennsylvania, 15232
6Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, 77030
7Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pennsylvania, 19104
8Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, 10029
°To whom correspondence should be addresses: joseph.buxbaum@mssm.edu; kathryn.roeder@gmail.com;
mjdaly@atgu.mgh.harvard.edu.
Author Contributions: Laboratory work: AS, CS, GC, OJ, ZP, JDB, DM, IN, YW, LL, YH, SG, ELC, NGC, ETG
Data Processing: BMN, KES, EL, AK, JF, MF, KS, TF, KG, EB, RP, MDP, SG, SY, VM, JL, JDB, AS, CS, UN, JGR, JRW, BEB,
SEL, CFL, LSW, OV
Statistical Analysis: BMN, LL, KES, CS, BFV, JM, ER, SS, PP, YK, AM, RD, CFL, LSW, HL, TZ, EB, RAG, JDB, CB, EHC, JSS,
GDS, BD, KR, MJD
PIs/Study design: EB, RAG, EHC, JDB, KR, BD, GDS, JSS, MJD; Yan Kou, Li Liu, Avi Ma'ayan, Kaitlin E. Samocha, Aniko Sabo,
and Chiao-Feng Lin contributed equally to this work. Eric Boerwinkle, Joseph D. Buxbaum, Edwin H. Cook, Jr., Bernie Devlin,
Richard A. Gibbs, Kathryn Roeder, Gerard D. Schellenberg, James S. Sutcliffe, and Mark J. Daly are lead investigators of the ARRA
Autism Sequencing Collaboration.
Author information: Data included in this manuscript has been deposited at dbGaP under accession number phs000298.v1.p1 and is
available for download at http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000298.v1.p1
Reprints and permissions information is available at http://www.nature.com/reprints.
The authors declare no competing financial interests.
Supplementary Information is linked to the online version of the paper at http://www.nature.com/nature
NIH Public Access
Author Manuscript
Nature. Author manuscript; available in PMC 2013 April 02.
Published in final edited form as:
Nature. ; 485(7397): 242–245. doi:10.1038/nature11011.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t9Division of Genetics, Department of Medicine Brigham & Women's Hospital and Harvard Medical
School, Boston, Massachusetts, 02115
10Vanderbilt Brain Institute, Departments of Molecular Physiology & Biophysics and Psychiatry,
Vanderbilt University, Nashville, Tennessee, 37232
11Biostatistics Department and Computer Science Department, Johns Hopkins University,
Baltimore, Maryland, 21205
12Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York, 10029
13Department of Pharmacology, University of Pennsylvania, Perelman School of Medicine,
Philadelphia, Pennsylvania 19104
14HudsonAlpha Institute for Biotechnology, Huntsville Alabama, 35806
15INSERM U952 and CNRS UMR 7224 and UPMC Univ Paris 06, 75005 Paris, France
16Human Genetics Center, University of Texas Health Science Center at Houston, Houston,
Texas, 77030
17Friedman Brain Institute, Mount Sinai School of Medicine, New York, New York, 10029
18Department of Psychiatry, University of Illinois at Chicago, Chicago, Illinois, 60608
19Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh,
Pennsylvania, 15213
Abstract
Autism spectrum disorders (ASD) are believed to have genetic and environmental origins, yet in
only a modest fraction of individuals can specific causes be identified1,2. To identify further
genetic risk factors, we assess the role of de novo mutations in ASD by sequencing the exomes of
ASD cases and their parents (n= 175 trios). Fewer than half of the cases (46.3%) carry a missense
or nonsense de novo variant and the overall rate of mutation is only modestly higher than the
expected rate. In contrast, there is significantly enriched connectivity among the proteins encoded
by genes harboring de novo missense or nonsense mutations, and excess connectivity to prior
ASD genes of major effect, suggesting a subset of observed events are relevant to ASD risk. The
small increase in rate of de novo events, when taken together with the connections among the
proteins themselves and to ASD, are consistent with an important but limited role for de novo
point mutations, similar to that documented for de novo copy number variants. Genetic models
incorporating these data suggest that the majority of observed de novo events are unconnected to
ASD, those that do confer risk are distributed across many genes and are incompletely penetrant
(i.e., not necessarily causal). Our results support polygenic models in which spontaneous coding
mutations in any of a large number of genes increases risk by 5 to 20-fold. Despite the challenge
posed by such models, results from de novo events and a large parallel case-control study provide
strong evidence in favor of CHD8 and KATNAL2 as genuine autism risk factors.
In spite of the substantial heritability, few genetic risk factors for ASD have been
identified1,2. Copy number variants (CNVs), often de novo and covering multiple adjacent
genes, have been identified as conferring risk3,4. While these CNVs provide important leads
to underlying biology, they rarely implicate single genes, are rarely fully penetrant, and
many confer risk to a broad range of conditions including intellectual disability(ID),
epilepsy, and schizophrenia5. There are also documented instances of rare single nucleotide
variants (SNVs) that are highly penetrant for ASD6.
Large-scale genetic studies make clear that the origins of ASD risk are multifarious, and
recent estimates based on CNV data put the number of independent risk loci in the
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thundreds4. Yet knowledge regarding specific risk-determining genes and the overall genetic
architecture for ASD remains incomplete. Although new sequencing technologies provide a
catalog of most variation in the genome, the profound locus heterogeneity of ASD makes it
challenging to distinguish variants that confer risk from the background noise of
inconsequential SNVs. De novo variation, being less frequent and potentially more
deleterious, could offer insights into risk-determining genes. For this reason we sought to
carefully evaluate the observed rate and consequence of de novo point mutations in the
exomes of ASD subjects.
We performed exome sequencing of 175 ASD probands and their parents across five centers
with multiple protocols and validation techniques (Supplementary Information). We used a
sensitive and specific analytic pipeline based on current best practices7-9 to analyze all data
and observed no heterogeneity of mutation rate among centers.
In the entire sample, we observed 161 coding region point mutations (101 missense, 50
silent and 10 nonsense), with an additional 2 conserved splice site (CSS) SNVs and 6
frameshift indels validated and included in pathway analyses (Supplementary Table 1).
To determine whether the rate of coding region point mutations was elevated, we estimated
the mutation rate in light of coverage and base context using two parallel approaches
(Supplementary Information). Based on both models, the exome target should have a
significantly increased (≈30%) mutation rate compared to the genome. Conservatively, by
assuming the low- end of the estimated mutation rate from recent whole-genome data
(1.2×10-8)10, we estimate a mutation rate of 1.5×10-8 for the exome sequence captured here.
The observed point mutation rate of 0.92/exome is slightly but not significantly elevated
versus expectation (Table 1) and is insensitive to adjustment for lower coverage regions
(Supplementary Information). Indeed our rate is similar to Sanders et al. (in press).
Per-family events were distributed according to the Poisson distribution (Table 1), yielding
no evidence for ASD tracing to high rates of de novo mutation. The relative rates of
‘functional’ (missense, nonsense, CSS and read-through) versus silent changes did not
deviate from expectation (Table 2). We did, however, observe 10 nonsense mutations
(6.2%), which exceeded expectation (3.3%) (one-tailed P=0.04; Supplementary
Information).
We examined the missense mutations as such variation can cause loss of function11 using
PolyPhen2 scores12 to measure mutation severity. These also showed no deviation from
random expectation. The observed PolyPhen2 scores clearly deviate from standing variation
in the parents (Table 2): Such variation, even the rarest category, has survived selective
pressure and is not an appropriate control for de novo events.
We observed 3 genes with two de novo mutations: BRCA2 (2 missense), FAT1 (2 missense)
and KCNMA1 (1 missense, 1 silent). A gene with two or more non-synonymous de novo
hits across a panel of trios might suggest strong candidacy. However, simulations
(Supplementary Information) show that two such hits are inadequate to define a gene as a
conclusive risk factor given the number of observed events in the study.
From analyses of secondary phenotypes (Supplementary Tables 2-3), the most striking result
is that paternal and maternal age, themselves highly correlated (r2=0.679, P-value<0.0001),
each strongly predicts the number of de novo events per offspring (paternal age P=0.0013,
maternal age P=0.000365), consistent with aggregating mutations in germ cells in the
paternal line13. Consistent with genetic theory, there is an increased rate of de novo mutation
in female versus male cases (1.214 for females vs. 0.914 for males); however, the difference
is not significant, perhaps owing to limited sample size. Considering phenotypic correlates,
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twe observed no rate difference between subjects with strict autism versus those with a
broader ASD diagnosis, between positive and negative family history, or any significant
effect of de novo mutation on verbal, nonverbal or full scale IQ (Supplementary Table 3).
While hundreds of loci are apparently involved in autism4 and de novo mutations therein
affect ASD risk, modeling of different numbers of risk genes and penetrances
(Supplementary Information) shows that a model of hundreds of genes with high penetrance
mutations is excluded by our data; however, more modest contributions of de novo variants
are not. For example, 10-20% of cases carrying a de novo risk-conferring event and
conferring ten to twentyfold increased risk, is consistent with these data (Supplementary
Table 4). Thus, our data are consistent with either chance mutation or a modest role for de
novo mutations on risk.
We therefore posed two questions of the group of genes harboring de novo functional
mutations: do the protein products of these genes interact with each other more than
expected, and are they unusually enriched in, or connected to, prior curated lists of ASD-
implicated genes? Using an in silico approach (DAPPLE)14,15 the protein-protein
connectivity in the set of 113 genes harboring ‘functional’ de novo mutations was evaluated.
These analyses (Figure 1) showed significantly greater connectivity amongst the de novo
identified proteins than would be expected by chance (P<0.001) (Supplementary
Information).
Querying previously-defined, manually-curated lists of genes6 associated with high risk for
ASD with and without ID(Supplementary Tables 5), and high risk ID genes (Supplementary
Tables 6), we asked whether there was significant enrichment for de novo mutations in these
genes. Five genes with ‘functional’ de novo events were previously associated with ASD
and/or ID (STXBP1, MEF2C, KIRREL3, RELN and TUBA1A); for four of these genes (all
but RELN) the prior evidence indicated autosomal dominant inheritance.
We then assessed the average distance (Di, Supplementary Figure 2) of the de novo coding
variants in brain-expressed genes (see supplement) to the ASD/ID list using a Protein-
Protein Interaction background network. To enhance power, data from a companion study
(Sanders et al.) were used, including the observed silent de novo variants and de novo
variants in unaffected siblings as comparators. The average distance for non-synonymous
variants was significantly smaller for the case set than the comparator set (3.66±0.42 versus
3.78±0.59; permutation P=0.033) (Figure 2). Much of this signal comes from 31 synaptic
genes identified by three large-scale synaptic proteomic studies (Di=3.47±0.46 versus
3.57±0.60; permutation P=0.084) (Supplemental Figure 3; see also Supplemental Fig. 4 for
the complete data). Taken in total, these independent gene set analyses, along with the
modest enrichment of de novo variants over background rates in ASD, indicate that a
proportion of the de novo events observed in this study likely contribute to autism risk.
Using whole-exome sequencing of autism trios, we demonstrate a rate, functional
distribution and predicted impact of de novo mutation largely consistent with chance
mutational processes governed by sequence context. This lack of significant deviation from
random mutational processes suggests a more limited role for the contribution of de novo
mutations to ASD pathogenesis than has previously been suggested15, and specifically
highlights the fact that observing a single de novo mutation, even an apparently ‘severe’
LOF allele, is insufficient to implicate a gene as a risk factor. Yet the pathway analyses
presented here assert that the overall set of genes hit with ‘functional’ de novo mutations are
not random and are biologically related to each other and to previously identified ASD/ID
candidate genes. Modeling the de novo mutational process under a range of genetic models
reveals that some models are inconsistent with the observed data – e.g., one hundred rare,
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tfully penetrant Mendelian genes similar to Rett syndrome – while others are not such as
spontaneous ‘functional’ mutation in a 1,000 genes that would increase risk by ten or
twentyfold (Supplementary Table 4). Models that fit the data are consistent with the relative
risks estimated for most de novo CNVs4 and suggest that de novo SNVs, like most CNVs,
often combine with other risk factors rather than fully cause disease. Furthermore, these
models suggest that de novo SNVs events will likely explain <5% of the overall variance in
autism risk (Supplementary Table 4).
Considering the two companion manuscripts, 18 genes with two functional de novo
mutations are observed in the complete data. Using simulations, 11.91 genes on average
harbor functional mutations by chance (Supplementary Table 7). Thus, a set of 18 genes
with two or more hits is not quite significant (p=0.063). Matching loss-of-function variants,
however, at SCN2A, KATNAL2 and CHD8 (Supplementary Table 7) are unlikely to occur
by chance because the expected very low rate of de novo nonsense, splice and frameshift
variants. We evaluated these strong candidates further using exome sequencing on 935 cases
and 870 controls and at both KATNAL2 and CHD8, three additional LoF mutations were
observed in cases with none in controls (no additional LoF mutations were seen at SCN2A).
Using data from more than 5000 individuals in the NHLBI Exome Variant Server as
additional controls, 3 LoF mutations were seen in KATNAL2 but none again in CHD8,
making the additional observation of 3 CHD8 LoF mutations in our cases significant
evidence (p<0.01) of this being a genuine autism susceptibility gene. Not all genes with
double hits are nearly so promising (Supplementary Information; Supplementary Tables 8-9)
supporting the estimate above that most such observations are simply chance events.
Overall, these data underscore the challenge of establishing individual genes as conclusive
risk factors for ASD, a challenge that will require larger sample sizes and, likely, deeper
analytic integration with inherited variation.
Methods (for online version only)
Phenotype assessment
Affected probands were assessed by research-reliable research personnel using Autism
Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule-
Generic (ADOS) and DSM-IV diagnosis of a pervasive developmental disorder was made
by a clinician. All probands met criteria for autism on the ADI-R and either autism or ASD
on the ADOS, except for the 3 subjects from AGRE that were not assessed with the ADOS.
In all 85% of probands were classified with autism on both the ADI-R and ADOS. All
subjects provided informed consent and the research was approved by institutional human
subjects board.
Exome sequencing, variant identification, and de novo detection
Exome capture and sequencing was performed at each site using similar methods. Exons
were captured using the Agilent 38Mb SureSelect v2 (University of Pennsylvania and Broad
Institute n=118), the NimbleGen Seq Cap EZ SR v2 (Mt Sinai School of Medicine,
Vanderbilt University n=51), or NimbleGen VCRome 2.1 (Baylor n=6). After capture,
another round of LM-PCR was performed to increase the quantity of DNA available for
sequencing. All libraries were sequenced using an IlluminaHiSeq2000.
Sequence processing and variant calling was performed using a similar computational
workflow at all sites. Data was processed with Picard (http://picard.sourceforge.net/), which
utilizes base quality-score recalibration and local realignment at known indels8 and BWA7
for mapping reads to hg19. SNPs were called using GATK8,9 for all trios jointly. The
variable sites that we have considered in analysis are restricted to those that pass GATK
standard filters. From this set of variants, we identified putative de novo mutations as sites
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heterozygous and each genotype call was made confidently (see Supplementary
Information).
Validation of de novo events
Putative de novo events were validated by sequencing the carrier and both parents using
Sanger sequencing methods (University of Pennsylvania, Mt. Sinai School of Medicine,
Vanderbilt University, Baylor Medical College) or by Sequenom MALDI-TOF genotyping
of trios (Broad).
Gene annotation
All identified mutations were then annotated using Refseq hg19. The functional impact of
variants was assessed for all isoforms of each gene, with the most severe annotation taking
priority. Splice site variants were identified as occurring within two basepairs of any intron/
exon boundary.
Expectation of de novo mutation calculation
To calculate the expected de novo rate, we assessed the mutability of all possible
trinucleotide contexts in the intergenic region of the human genome for variation in two
fashions: fixed genomic differences compared to chimpanzee and baboon12 and variation
identified from the 1,000 Genomes project. The overall mutation rate for the exome was
then determined by summing the probability of mutation for all bases in the exome that were
captured successfully. We also determined the probability of each class functional mutation
by summing the annotated variants.
Pathway analyses
We applied DAPPLE14, which uses the InWeb database15, to determine whether there is
excess protein protein interaction across the genes hit by a functional de novo event. We
also assessed whether these genes were more closely connected to a list of ASD genes.6
Modeling de novo events
We modeled a Poisson process consistent with the expected distribution defined by the
mutation model and with the observed data. We varied the fraction of genes that influence
risk, the probability a variant in a gene would be functional, and the penetrance of functional
de novo events. We also simulated a random set of de novo events to estimate the
probability of hitting a gene multiple times.
Association Analysis
We performed association tests using SKAT17, a generalization of C-alpha18. Our primary
analyses treat case-control data generated at Baylor and Broad separately (23 genes X 2
sites), but we also performed mega and meta-analyses (23 genes X 2 methods).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Protein-Protein interaction for genes with an observed functional de novo event
Direct protein connections from InWeb, restricting to genes harboring de novo mutations for
DAPPLE analysis. Two extensive networks are identified, the first centered on SMARCC2
with 12 connections across 11 genes and the second centered on FN1 with 7 connections
across 6 genes. The P-value for each gene having as many connections as those observed
color the nodes of the network.
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tFigure 2. Direct and indirect Protein-Protein interaction for genes with a functional de novo
event and existing ASD/ID genes
PPI network analysis for de novo variants and prior ASD genes (ASD112). Nodes are sized
based on connectivity. Genes harboring de novo variants (left) and prior ASD genes (right)
are colored blue with dark blue nodes represent genes that belong to one of these lists and
are also intermediate proteins. Intermediate proteins (center) are colored in shades of orange
based on a p-value computed using a proportion test where darker color represents a lower
p-value. Green edges represent direct connections between genes harboring de novo variants
(left) and prior ASD genes. All other edges, connecting to intermediate proteins are shown
in grey.
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Table 1
Distribution of Events Per Family.
Events per
family
All ASD trios
Random
Mut-Exp3 exon DN
SNVs
Exp
0 71 69.7 73.2
1 62 64.2 63.8
2 28 29.5 27.8
3 10 9.1 8.1
4 2 2.1 1.8
5 1 0.4 0.3
0.920 0.871
1
exon DN-SNVs include all single nucleotide variants in coding sequence but excludes indels and intronic variants
2
exp is the expected distribution of number of trios with a given event count as determined by the Poisson
3
Random Mut-Exp is the expectation for 175 trios based on the sequence-context mutation rate model M1 (Supplementary Materials) based on the
count of the number of trios that have at least 10× coverage.
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